EP0871449A4 - - Google Patents

Info

Publication number
EP0871449A4
EP0871449A4 EP96912400A EP96912400A EP0871449A4 EP 0871449 A4 EP0871449 A4 EP 0871449A4 EP 96912400 A EP96912400 A EP 96912400A EP 96912400 A EP96912400 A EP 96912400A EP 0871449 A4 EP0871449 A4 EP 0871449A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96912400A
Other versions
EP0871449A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt ARD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EP0871449A4 publication Critical patent/EP0871449A4/xx
Publication of EP0871449A1 publication Critical patent/EP0871449A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96912400A 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits Withdrawn EP0871449A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002199615A CA2199615A1 (en) 1996-02-12 1996-02-12 Erythro-hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemia traits
PCT/US1996/001990 WO1997028803A1 (en) 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits

Publications (2)

Publication Number Publication Date
EP0871449A4 true EP0871449A4 (sk) 1998-10-21
EP0871449A1 EP0871449A1 (en) 1998-10-21

Family

ID=25679111

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96912400A Withdrawn EP0871449A1 (en) 1996-02-12 1996-02-12 Hydroxynonyladenine analogs with enhanced lipophilic and anti-ischemic traits

Country Status (4)

Country Link
EP (1) EP0871449A1 (sk)
AU (1) AU5522996A (sk)
CA (1) CA2199615A1 (sk)
WO (1) WO1997028803A1 (sk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP921299A0 (en) * 1999-03-15 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE102015009609B4 (de) 2015-07-22 2024-08-22 Thomas Podzuweit Glykostimulatorische Therapie von Krebs und Metastasen: Biologisch-metabolische Krebsabwehr

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE826935A (fr) * 1975-02-13 1975-09-22 Compositions pharmaceutiques antivirales
WO1994017809A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine deaminase inhibitor therapies
US5491146A (en) * 1993-01-14 1996-02-13 Cypros Pharmaceutical Corporation Hydroxylated erythro-hydroxynonyladenines and related analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221909A (en) * 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE826935A (fr) * 1975-02-13 1975-09-22 Compositions pharmaceutiques antivirales
US5491146A (en) * 1993-01-14 1996-02-13 Cypros Pharmaceutical Corporation Hydroxylated erythro-hydroxynonyladenines and related analogs
WO1994017809A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine deaminase inhibitor therapies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PHILLIS ET AL.: "Adenosine deaminase inhibitors enhance cerebral anoxic hyperemia in the rat", J. CEREBR. BLOOD FLOW METAB., vol. 5, no. 2, 1985, pages 295 - 299, XP002060877 *
SCHAEFFER ET AL.: "Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines", J. MED. CHEM., vol. 17, no. 1, 1974, pages 6 - 8, XP002060875 *
See also references of WO9728803A1 *
VERGEESE ET AL.: "Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine", J. MED. CHEM., vol. 37, no. 22, 28 October 1994 (1994-10-28), pages 3844 - 3849, XP002060876 *

Also Published As

Publication number Publication date
EP0871449A1 (en) 1998-10-21
AU5522996A (en) 1997-08-28
CA2199615A1 (en) 1997-08-14
WO1997028803A1 (en) 1997-08-14

Similar Documents

Publication Publication Date Title
AR026660A2 (sk)
BRPI9713914B8 (sk)
ITCA960011A0 (sk)
BR7600721U (sk)
BR7601346U (sk)
BR9603859A (sk)
CN3039060S (sk)
CN3039213S (sk)
CN3040024S (sk)
CN3040367S (sk)
CN3040543S (sk)
CN3040805S (sk)
CN3041207S (sk)
CN3041374S (sk)
CN3041383S (sk)
CN3042289S (sk)
CN3042589S (sk)
CN3043305S (sk)
CN3044168S (sk)
CN3044346S (sk)
CN3044347S (sk)
CN3044348S (sk)
CN3044349S (sk)
CN3045208S (sk)
CN3045530S (sk)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971111

A4 Supplementary search report drawn up and despatched

Effective date: 19980428

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QUESTCOR PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20000926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010206